RWA Wealth Partners LLC Buys 21,231 Shares of Eli Lilly and Company $LLY

RWA Wealth Partners LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 49.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 64,533 shares of the company’s stock after purchasing an additional 21,231 shares during the period. Eli Lilly and Company accounts for about 0.6% of RWA Wealth Partners LLC’s investment portfolio, making the stock its 25th biggest position. RWA Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $50,305,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of LLY. Lazard Freres Gestion S.A.S. raised its position in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after acquiring an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC grew its stake in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK grew its stake in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the last quarter. Family CFO Inc bought a new position in Eli Lilly and Company in the second quarter worth about $54,000. Finally, Duquesne Family Office LLC lifted its position in shares of Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 4,314 shares of company stock valued at $2,766,929. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

NYSE LLY opened at $923.35 on Friday. The company has a market cap of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock’s fifty day moving average price is $799.97 and its 200 day moving average price is $775.76. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LLY shares. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, JPMorgan Chase & Co. dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $960.88.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.